Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

New Perioperative Strategies Emerge for High-Risk, Resectable RCC

December 4th 2019

The current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.

Dr. Beckermann on Sequencing Strategies in mRCC

December 4th 2019

Kathryn E. Beckermann, MD, PhD, instructor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, discusses sequencing strategies in metastatic renal cell carcinoma (mRCC).

Dr. Davis on IMvigor130 Trial in Metastatic Urothelial Cancer

December 3rd 2019

Nancy B. Davis, MD, discusses the results of the phase III IMvigor130 trial in metastatic urothelial cancer.

Breadth of RCC Treatment Options Includes Novel Agents and Combo Strategies

December 2nd 2019

Kathryn E. Beckermann, MD, PhD, discusses the available single-agent and combination options for the treatment of patients with metastatic renal cell carcinoma.

FDA Label Change Takes a Bite Out of Prescriptions

November 26th 2019

Immunotherapy prescriptions for patients with metastatic bladder cancer declined rapidly after the FDA altered the indications of 2 drugs, suggesting that oncologists can keep pace with changes associated with the agency’s accelerated approval program.

Dr. Castle on Minimally Invasive Surgical Approaches in RCC

November 20th 2019

Erik P. Castle, MD, discusses minimally invasive surgical approaches in renal cell carcinoma.

Erdafitinib Tackles an Unmet Need in Urothelial Carcinoma

November 14th 2019

As the first targeted therapy in bladder cancer, erdafitinib (Balversa) expands the limited treatment options for the subset of patients with urothelial carcinoma.

Cytoreductive Nephrectomy in mRCC Paradigm Requires Careful Patient Selection

November 14th 2019

Erik P. Castle, MD, discusses the role of cytoreductive nephrectomy in renal cell carcinoma based on interpretation of the CARMENA trial results.

Frontline Setting in mRCC Continues to Evolve With Combo Regimens

November 12th 2019

Thai H. Ho, MD, PhD, discusses frontline treatment considerations in metastatic renal cell carcinoma, the utility of TKI monotherapy, and new combinations on the horizon.

Dr. Jonasch on Modulating the Tumor Microenvironment in RCC

November 12th 2019

Eric Jonasch, MD, discusses how to modulate the tumor microenvironment in renal cell carcinoma.

Dr. Ho on First-Line TKI Monotherapy in mRCC

November 12th 2019

Thai H. Ho, MD, PhD, discusses the role of TKI monotherapy in the first-line treatment of patients with metastatic renal cell carcinoma.

Dr. McDermott on TKI/Immunotherapy Combinations in RCC

November 12th 2019

David F. McDermott, MD, discusses the combination of VEGF TKIs and PD-1 inhibitors in advanced renal cell carcinoma.

Expert Compares Frontline Immunotherapy Studies in RCC

November 8th 2019

Three game-changing immunotherapy trials have transformed the treatment paradigm in frontline clear cell renal cell carcinoma. At the 37th Annual CFS®, Robert J. Motzer, MD, compared the findings from the three studies.

Dr. Motzer on First-Line Treatment of Metastatic RCC

November 7th 2019

Robert J. Motzer, MD, discusses the first-line treatment landscape of metastatic clear cell renal cell carcinoma.

Dr. Sonpavde on the Safety Profile of Erdafitinib in Bladder Cancer

November 2nd 2019

Guru P. Sonpavde, MD, discusses the safety profile of erdafitinib, which was approved by the FDA in April 2019 to treat adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy.

Dr. Powles on Design and Findings of the BISCAY Trial in Platinum-Refractory Urothelial Cancer

October 31st 2019

Thomas Powles, MD, MBBS, MRCP, professor, Genitourinary Oncology, lead for Solid Tumour Research, and director, Barts Cancer Institute, discusses the design and findings of the phase Ib BISCAY trial in platinum-refractory urothelial cancer.

Avelumab/Axitinib Combo Approved in Europe for Frontline RCC

October 29th 2019

The European Commission has approved the combination of avelumab and axitinib for the frontline treatment of adult patients with advanced renal cell carcinoma.

Dr. Sonpavde on Neoadjuvant Immunotherapy in Bladder Cancer

October 26th 2019

Guru P. Sonpavde, MD, discusses current neoadjuvant immunotherapy options in bladder cancer based on cisplatin eligibility status.

Novel Immunotherapy Combos Target GITR to Step on the Gas

October 22nd 2019

Immunotherapies designed to exploit the host immune system to specifically target cancer cells exploded onto the oncology scene in the mid-1980s, when the first such agents started to show success in melanoma and renal cell carcinoma.

Dr. McGregor on Unmet Needs in Non-Clear Cell RCC

October 21st 2019

Bradley McGregor, MD, discusses the challenges of developing treatment strategies for patients with non-cell clear renal cell carcinoma.